HIV vaccine development and clinical trials

R. Hoff, J. McNamara, Mary Glenn Fowler, M. McCauley

Research output: Contribution to journalArticle


The magnitude of HIV pandemic has made the development of HIV vaccines an urgent biomedical research priority. Although the biologic problems in designing a vaccine for a chronic viral infection like HIV are formidable, there has been encouraging progress. More than a dozen first generation prophylactic HIV vaccine candidates have completed phase I human trials that have established the safety and immunogenicity of these products in adults. A phase II trial of two HIV subunit envelope vaccines in adults at high risk of HIV infection is underway in the United States, and preparations for phase III efficacy trials have begun. Preliminary studies are under way to evaluate the potential application of active and passive immunization for preventing vertical transmission of HIV. Because of the higher rate of HIV transmission and a more abbreviated time course to disease, it may be more efficient to evaluate the efficacy of HIV vaccines in HIV infected pregnant women and their offspring than in adults who are exposed sexually to HIV.

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalActa paediatrica (Oslo, Norway : 1992). Supplement
Issue number400
Publication statusPublished - 1994
Externally publishedYes



  • clinical trials
  • HIV vaccines
  • human immunodeficiency virus (HIV)
  • immune globulin
  • vertical transmission

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this